LNWWM
TEVA icon

Laird Norton Wetherby Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13,695
Closed -$211K – 679
2018
Q4 		$211K Sell
13,695
-4,216
-24% -$86.4K 0.03% 571
2018
Q3 		$386K Buy
17,911
+683
+4% +$15.9K 0.05% 430
2018
Q2 		$419K Buy
17,228
+3,963
+30% +$80.8K 0.06% 389
2018
Q1 		$227K Buy
13,265
+2,857
+27% +$55.8K 0.03% 569
2017
Q4 		$197K Buy
+10,408
New +$157K 0.03% 602
2017
Q3 		– Sell
-9,374
Closed -$311K – 642
2017
Q2 		$311K Buy
9,374
+653
+7% +$20.2K 0.05% 422
2017
Q1 		$280K Sell
8,721
-1,424
-14% -$48.6K 0.05% 443
2016
Q4 		$368K Sell
10,145
-2,058
-17% -$82.2K 0.07% 352
2016
Q3 		$562K Buy
12,203
+2,120
+21% +$111K 0.11% 230
2016
Q2 		$507K Sell
10,083
-366
-4% -$19.5K 0.11% 218
2016
Q1 		$559K Sell
10,449
-434
-4% -$25.5K 0.13% 186
2015
Q4 		$715K Buy
10,883
+195
+2% +$12.1K 0.17% 129
2015
Q3 		$604K Buy
10,688
+884
+9% +$57.3K 0.15% 155
2015
Q2 		$579K Buy
9,804
+432
+5% +$26.6K 0.14% 178
2015
Q1 		$584K Buy
9,372
+257
+3% +$14.9K 0.14% 171
2014
Q4 		$524K Buy
9,115
+728
+9% +$40.6K 0.13% 182
2014
Q3 		$450K Buy
8,387
+114
+1% +$6.04K 0.13% 198
2014
Q2 		$434K Sell
8,273
-210
-2% -$10.7K 0.12% 204
2014
Q1 		$448K Buy
8,483
+274
+3% +$12.7K 0.13% 203
2013
Q4 		$329K Sell
8,209
-570
-6% -$22.4K 0.09% 270
2013
Q3 		$331K Buy
8,779
+1,453
+20% +$56.7K 0.1% 249
2013
Q2 		$288K Buy
+7,326
New +$285K 0.1% 242

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's TEVA Position: Q1 2019 in Review

Laird Norton Wetherby Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2019, closing a stake of 13,695 shares — an estimated $211K sold.

Laird Norton Wetherby Wealth Management first reported a position in TEVA in Q2 2013 and held it in 22 quarters. The position peaked at $715K in Q4 2015. 521 funds tracked by Wall St. Rank hold TEVA as of Q1 2019.

  • Laird Norton Wetherby Wealth Management reported no remaining Teva Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Laird Norton Wetherby Wealth Management sold 13,695 Teva Pharmaceuticals shares in Q1 2019, an estimated $211K.
  • Laird Norton Wetherby Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Laird Norton Wetherby Wealth Management's Teva Pharmaceuticals position peaked at $715K in Q4 2015.
  • 521 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2019.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q1 2019, filed 9 May 2019.